1. Home
  2. CRON vs NVCR Comparison

CRON vs NVCR Comparison

Compare CRON & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cronos Group Inc.

CRON

Cronos Group Inc.

HOLD

Current Price

$2.59

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$11.85

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRON
NVCR
Founded
N/A
2000
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
CRON
NVCR
Price
$2.59
$11.85
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$28.08
AVG Volume (30 Days)
1.8M
964.3K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
$146,587,000.00
$655,353,000.00
Revenue This Year
$26.34
$7.72
Revenue Next Year
$15.53
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
24.63
8.28
52 Week Low
$1.81
$9.82
52 Week High
$3.43
$20.05

Technical Indicators

Market Signals
Indicator
CRON
NVCR
Relative Strength Index (RSI) 47.55 48.89
Support Level $2.45 $10.72
Resistance Level $2.73 $13.30
Average True Range (ATR) 0.14 0.58
MACD -0.00 0.05
Stochastic Oscillator 9.46 52.35

Price Performance

Historical Comparison
CRON
NVCR

About CRON Cronos Group Inc.

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: